Zylox-Tonbridge Revenue Jumps 31% as Global Strategy Takes Hold

Net profit for the six-month period climbed 47.8% to RMB 179 million, bolstered by improved margins of 73.4% for gross profit and 28.3% for net profit. While the company maintained a firm grip on domestic market share, international sales now account for over 11% of total revenue. The acquisition of a 60% stake in optimed in April proved pivotal, allowing the company to establish direct sales networks across Germany, France, and Austria. This European footprint is now a primary engine for growth, with EMEA contributing 76% of all international income. The company currently reaches more than 80% of group purchasing organizations in its core French and German markets.

Global Scaling and Clinical Expansion

Beyond Europe, the firm expanded its reach into Latin America and the Asia-Pacific region, marking the first clinical use of its Zynlastic Peripheral Venous Stent and ZYLOX Unicorn Vascular Closure System in Brazil and South Korea. Domestic operations remain buoyed by a steady flow of regulatory wins, with 11 new products receiving NMPA approval during the period. The company continues to prioritize its innovation pipeline, with 10 products currently under the NMPA's Special Review Procedure for Innovative Medical Devices. By aligning its precision engineering with unified supply-chain management, the firm has successfully integrated its product portfolio across more than 135 countries.